Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 36, Issue 2, 2012, Pages 300-306

  Kitajima, Rei ^a   Miyamoto, Seiya ^a   Tenjin, Tomomi ^a   Ojima, Kazuaki ^a   Ogino, Shin ^a   Miyake, Nobumi ^a   Fujiwara, Keisuke ^a   Funamoto, Yasuyuki ^b   Arai, Jun ^a   Tsukahara, Sachiko ^a   Ito, Yukie ^a   Tadokoro, Masanori ^a   Anai, Kiriko ^a   Kaneda, Yasuhiro ^c   Yamaguchi, Noboru ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Psychiatry   (Japan)

^c Iwaki Clinic   (Japan)

Author keywords

Benzodiazepines; Cognitive function; Quality of life; Schizophrenia; Second generation antipsychotics

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; BLONANSERIN; BROMAZEPAM; BROTIZOLAM; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DIAZEPAM; ETIZOLAM; FLUNITRAZEPAM; FLUVOXAMINE; LORAZEPAM; LORMETAZEPAM; NEUROLEPTIC AGENT; NITRAZEPAM; OLANZAPINE; PEROSPIRONE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; VALPROIC ACID;

ADULT; ARTICLE; BEDTIME DOSAGE; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG USE; FEMALE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MALE; MOTIVATION; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SCHIZOPHRENIA QUALITY OF LIFE SCALE; VERBAL MEMORY; WORKING MEMORY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84855357141     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.11.008     Document Type: Article

References (58)

1. Allgulander C., Bandelow B., Hollander E., Montgomery S.A., Nutt D.J., Okasha A., et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003, 8:53-61.
2. American Psychiatric Association Diagnostic criteria from DSM-IV-TR 2000, American Psychiatric Association, Washington, D.C.
3. Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict 1987, 82:665-671.
4. Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs 1994, 48:25-40.
5. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005, 18:249-255.
6. Baillargeon L., Landreville P., Verreault R., Beauchemin J.P., Gregoire J.P., Morin C.M. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ 2003, 169:1015-1020.
7. Barker M.J., Greenwood K.M., Jackson M., Crowe S.F. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004, 18:37-48.
8. Barker M.J., Greenwood K.M., Jackson M., Crowe S.F. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 2004, 19:437-454.
9. Barker M.J., Greenwood K.M., Jackson M., Crowe S.F. An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. J Int Neuropsychol Soc 2005, 11:281-289.
10. Chakos M.H., Glick I.D., Miller A.L., Hamner M.B., Miller D.D., Patel J.K., et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006, 57:1094-1101.
11. Crespo-Facorro B., Rodriguez-Sanchez J.M., Perez-Iglesias R., Mata I., Ayesa R., Ramirez-Bonilla M., et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry 2009, 70:717-729.
12. Curran H.V., Collins R., Fletcher S., Kee S.C., Woods B., Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med 2003, 33:1223-1237.
13. Fleischhacker W.W. New developments in the pharmacotherapy of schizophrenia. J Neural Transm Suppl 2003, 105-117.
14. Gillies D., Beck A., McCloud A., Rathbone J. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev 2005, CD003079.
15. Gold J.M., Harvey P.D. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993, 16:295-312.
16. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
17. Guy W. Clinical global impressions 1976, US Department of Health and Human Services Publication (ADM, Rockville, MD.
18. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001, 158:176-184.
19. Higuchi H., Kamata M., Yoshimoto M., Shimisu T., Hishikawa Y. Panic attacks in patients with chronic schizophrenia: a complication of long-term neuroleptic treatment. Psychiatry Clin Neurosci 1999, 53:91-94.
20. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006, 86:138-146.
21. Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage 1996, Seiwa Shoten Publishers, Tokyo.
22. Inada T., Beasley C.M., Tanaka Y., Walker D.J. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 2003, 18:39-48.
23. Kane J.M. Schizophrenia. N Engl J Med 1996, 334:34-41.
24. Kaneda Y., Imakura A., Fujii A., Ohmori T. Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Res 2002, 113:107-113.
25. Kaneda Y., Sumiyoshi T., Keefe R., Ishimoto Y., Numata S., Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci 2007, 61:602-609.
26. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
27. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004, 68:283-297.
28. Keefe R.S.E., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999, 25:201-222.
29. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
30. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
31. Minzenberg M.J., Poole J.H., Benton C., Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004, 161:116-124.
32. Miyamoto, S., Fleischhacker, W.W., Lieberman, J.A., in press. Pharmacologic treatment of schizophrenia. in: Murray, R., Lieberman, J.A. (Eds.), Comprehensive care of schizophrenia, Oxford University Press, New York.
33. Miyamoto S., Stroup T.S., Duncan G.E., Aoba A., Lieberman J.A. Acute pharmacologic treatment of schizophrenia. Schizophrenia 2003, 442-473. Blackwell Science, Oxford. Second edition. S.R. Hirsch, D.R. Weinberger (Eds.).
34. Morin C.M., Belanger L., Bastien C., Vallieres A. Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse. Behav Res Ther 2005, 43:1-14.
35. Ogino S., Miyamoto S., Tenjin T., Kitajima R., Ojima K., Miyake N., et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:78-83.
36. Petursson H. The benzodiazepine withdrawal syndrome. Addiction 1994, 89:1455-1459.
37. Pollack M.H. Innovative uses of benzodiazepines in psychiatry. Can J Psychiatry 1993, 38(Suppl 4):S122-S126.
38. Poyares D., Guilleminault C., Ohayon M.M., Tufik S. Chronic benzodiazepine usage and withdrawal in insomnia patients. J Psychiatr Res 2004, 38:327-334.
39. Reine G., Lancon C., Di Tucci S., Sapin C., Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand 2003, 108:297-303.
40. Rickels K., DeMartinis N., Rynn M., Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999, 19:12S-16S.
41. Shinfuku N., Tan C.H. Pharmacotherapy for schizophrenic inpatients in East Asia-changes and challenges. Int Rev Psychiatry 2008, 20:460-468.
42. Silver H., Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A Double-blind cross-over study. Br J Psychiatry 1995, 166:241-243.
43. Stewart S.A. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005, 66(Suppl 2):9-13.
44. Strauss M.E., Reynolds K.S., Jayaram G., Tune L.E. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res 1990, 3:127-129.
45. Tata P.R., Rollings J., Collins M., Pickering A., Jacobson R.R. Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychol Med 1994, 24:203-213.
46. Tolman A.W., Kurtz M.M. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull. 2010 Jul 11, [Electronic publication ahead of print].
47. Tomida K., Takahashi N., Saito S., Maeno N., Iwamoto K., Yoshida K., et al. Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin Neurosci 2010, 64:62-69.
48. Tor P.C., Ng T.P., Yong K.H., Sim K., Xiang Y.T., Wang C.Y., et al. Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008. Int J Neuropsychopharmacol 2011, 14:735-745.
49. Tyrer P., Rutherford D., Huggett T. Benzodiazepine withdrawal symptoms and propranolol. Lancet 1981, 1:520-522.
50. Ueoka Y., Tomotake M., Tanaka T., Kaneda Y., Taniguchi K., Nakataki M., et al. Quality of life and cognitive dysfunction in people with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:53-59.
51. Wegener S., Redoblado-Hodge M.A., Lucas S., Fitzgerald D., Harris A., Brennan J. Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. Aust N Z J Psychiatry 2005, 39:487-492.
52. Wilkinson G., Hesdon B., Wild D., Cookson R., Farina C., Sharma V., et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000, 177:42-46.
53. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8:457-472.
54. Woon P.S., Chia M.Y., Chan W.Y., Sim K. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:463-468.
55. Yamauchi K., Aki H., Tomotake M., Iga J., Numata S., Motoki I., et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin Neurosci 2008, 62:404-411.
56. Yamawaki S. The use and development of anxiolytics in Japan. Eur Neuropsychopharmacol 1999, 9(Suppl 6):S413-S419.
57. Yoshio T., Uno J., Nakagawa M., Hasegawa T., Sugimura K., Umeda K., et al. Survey of the prescriptions for psychotherapy in Japanese inpatients with schizophrenia in 2006. Jpn J Clin Psychopharmacol 2010, 13:1535-1545.
58. Zitman F.G., Couvee J.E. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry 2001, 178:317-324.